27,052 Shares in Anavex Life Sciences Corp. (NASDAQ:AVXL) Bought by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. acquired a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 27,052 shares of the biotechnology company’s stock, valued at approximately $291,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its holdings in Anavex Life Sciences by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company’s stock worth $242,000 after purchasing an additional 1,191 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Anavex Life Sciences by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,980 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 1,671 shares during the last quarter. Foster Victor Wealth Advisors LLC raised its holdings in Anavex Life Sciences by 5.6% during the fourth quarter. Foster Victor Wealth Advisors LLC now owns 37,663 shares of the biotechnology company’s stock worth $405,000 after purchasing an additional 2,000 shares during the last quarter. Opus Capital Group LLC raised its holdings in Anavex Life Sciences by 6.1% during the fourth quarter. Opus Capital Group LLC now owns 34,700 shares of the biotechnology company’s stock worth $373,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Carnegie Investment Counsel raised its holdings in Anavex Life Sciences by 4.7% during the fourth quarter. Carnegie Investment Counsel now owns 76,778 shares of the biotechnology company’s stock worth $825,000 after purchasing an additional 3,445 shares during the last quarter. 31.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on AVXL shares. D. Boral Capital reaffirmed a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a report on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and issued a $42.00 price target on shares of Anavex Life Sciences in a report on Tuesday, February 18th.

Anavex Life Sciences Stock Up 0.8 %

NASDAQ AVXL opened at $7.91 on Friday. Anavex Life Sciences Corp. has a fifty-two week low of $3.25 and a fifty-two week high of $14.44. The stock has a market cap of $672.86 million, a price-to-earnings ratio of -14.38 and a beta of 0.69. The business has a fifty day moving average of $9.89 and a 200-day moving average of $7.84.

Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. As a group, analysts anticipate that Anavex Life Sciences Corp. will post -0.69 EPS for the current year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.